The Human Variable 

Why rheumatoid arthritis is often misdiagnosed or delayed. Learn early RA symptoms, diagnostic gaps, and how CDF-RA™ improves early detection.

A field guide for designing Lyme disease clinical trials that work. Learn how to improve outcomes using adaptive design, co-infection stratification, digital biomarkers, and CYNAERA’s stabilization-first framework.

The Target Readiness Index™ (TRI) introduces a state-dependent framework for CRISPR target prioritization across ME/CFS, Long COVID, Lyme disease, and autoimmune conditions including lupus, type 1 diabetes, Hashimoto’s, and Sjögren’s.

SymCas™ is a flare prediction model for POTS, Lyme disease, ME/CFS, Long COVID and relapsing chronic conditions. It identifies symptom patterns over time to detect early instability and support proactive care.

The true U.S. burden of Lyme disease is estimated at 5 - 7 million Americans, according to CYNAERA’s US-CCUC™ 2026 prevalence model, substantially higher than the roughly 400,000 to 500,000 diagnoses recorded annually. By accounting for underdiagnosis, chronic illness, and fragmented surveillance, this paper reframes Lyme disease as a major chronic illness burden rather than a narrowly counted regional infection.

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.